ArticleBlood cell therapy2025
REAL-WORLD OUTCOMES OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE TREATED WITH RUXOLITINIB.
Article in Blood cell therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-term follow-up of ruxolitinib pre-approval use in acute and chronic graft-versus-host disease.Annals of hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute graft-versus-host disease (aGVHD) is a life-threatening complication that can develop after allogeneic hematopoietic stem cell transplantation. Patients with steroid-refractory aGVHD (SR-aGVHD) have an extremely poor prognosis. Ruxolitinib is an approved treatment for SR-aGVHD. However, there is a paucity of real-world data on the clinical outcomes of patients with SR-aGVHD treated with ruxolitinib. We conducted a retrospective analysis using hospital records of the clinical outcomes of patients who underwent stem cell transplantation at our center between January 2021 and December 2022 and developed steroid-refractory aGVHD which was treated with ruxolitinib. During the study period, 381 patients underwent allogeneic stem cell transplantation at our center. Amongst these, 160 (42.0%) developed aGVHD. Of these, 59 (36.8%) had SR-aGVHD and 40 were treated with ruxolitinib. Ruxolitinib therapy was administered after a median of 6 days (range 3-29) from onset of aGVHD. Amongst the 28 patients who survived at day 28 (12 died before the day 28 response could be assessed), a total of 16 patients (57.1%) attained a response (complete response (n=12) or partial response (n=4)). Infectious complications were the most common adverse event (n=39; 97.5%), followed by severe cytopenia (grades 3 to 4) in 25 (62.5%) patients. The median follow-up of the cohort was 5 months (range 1 to 29 months). At the last follow up, 30 (75%) patients died; 3 patients died of progression of steroid-refractory aGVHD, 14 died of progression of aGVHD with infection, 10 died of underlying infection and 3 had disease relapse. From our real-world analysis, we conclude that though the outcomes in patients with SR-aGVHD responding to ruxolitinib are encouraging, there is still a large unmet need for novel strategies for improving outcomes and reducing infection-related mortality, even while there is access to ruxolitinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.